FLT3: ITDoes matter in leukemia

Research output: Contribution to journalReview article

Abstract

FMS-like tyrosine kinase-3 (FLT3), a receptor tyrosine kinase, is important for the development of the hematopoietic and immune systems. Activating mutations of FLT3 are now recognized as the most common molecular abnormality in acute myeloid leukemia, and FLT3 mutations may play a role in other hematologic malignancies as well. The poor prognosis of patients harboring these mutations renders FLT3 an obvious target of therapy. This review summarizes the data on the molecular biology and clinical impact of FLT3 mutations, as well as the therapeutic potential of several small-molecule FLT3 inhibitors currently in development.

Original languageEnglish (US)
Pages (from-to)1738-1752
Number of pages15
JournalLeukemia
Volume17
Issue number9
DOIs
StatePublished - Sep 1 2003

    Fingerprint

Keywords

  • AML
  • FLT3
  • ITD
  • Receptor tyrosine kinase
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this